Very nice to see cohort 2 is now wrapped up, with no dose limiting toxicities... that's actually really good news because there was always a chance the dual administration could lead to complications... though it has been done before, never with CLTX CAR-T. Another big box ticked... and now cohort 3 is recruiting, and will accelerated early 2022 once the two new trial sites open up... data will then be generated at 3 sites, vs 1.. so what took 6 months, can now be done in 2!
and if they wait unti first week of June for the ASCO conference... that's near 6 months follow up for all patients in the second cohort... 75% disease control at the lowest dose... what is cohort 2 going to bring ,with double that low dose and dual administration....
goodluck all!
Ann: Successful completion of 2nd dose cohort in CLTX CAR T trial, page-2
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| CHM (ASX) Chart |
Day chart unavailable